Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SILENCE-NEUROMA Trial
NCT07431944Not yet recruiting
- Sponsor
- Superhuman
- Start
- Feb 2026
- Primary completion
- Feb 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of botulinum toxin type A in Neuroma (2 arms), sponsored by Superhuman. Primary endpoint: Change in neuroma-related pain intensity at 8 weeks. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
Neuroma
Beyond the preview
Go deeper on NCT07431944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07431944.